NCT01783691View on ClinicalTrials.gov

Safety, Pharmacokinetic, and Pharmacodynamic Study of NKTT120 in Adult Patients With Stable Sickle Cell Disease (SCD)

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Sickle Cell Disease
Interventions
DRUG

NKTT120

Trial Locations (6)

21205

Johns Hopkins School of Medicine, Baltimore

27514

UNC Sickle Cell Program, Chapel Hill

53226

Blood Center of Wisconsin, Milwaukee

63110

Washington University School of Medicine, St Louis

94609

Children's Hospital & Research Center at Oakland, Oakland

02115

Brigham and Women's Hospital, Boston

Sponsors

Lead Sponsor

NKT Therapeutics
All Listed Sponsors
lead

NKT Therapeutics

INDUSTRY